文章：

阿昔替尼在舒尼替尼或细胞因子治疗失败后用于晚期肾细胞癌——临床与真实世界证据的系统文献综述

Axitinib after Treatment Failure with Sunitinib or Cytokines in Advanced Renal Cell Carcinoma—Systematic Literature Review of Clinical and Real-World Evidence

原文发布日期：30 July 2024

DOI: 10.3390/cancers16152706

类型: Article

开放获取: 是

英文摘要：

Background: We conducted a systematic literature review (SLR) to identify clinical evidence on treatments in advanced renal cell carcinoma (aRCC) after the failure of prior therapy with cytokines, tyrosine kinase inhibitors, or immune checkpoint inhibitors. Herein, we summarise the evidence for axitinib in aRCC after the failure of prior therapy with cytokines or sunitinib. Methods: This SLR was registered with PROSPERO (CRD42023492931) and followed the 2020 PRISMA statement and the Cochrane guidelines. Comprehensive searches were conducted in MEDLINE and Embase as well as for conference proceedings. Study eligibility was defined according to population, intervention, comparator, outcome, and study design. Results: Of 1252 titles/abstracts screened, 266 peer-reviewed publications were reviewed, of which 182 were included. In addition, 28 conference abstracts were eligible. Data on axitinib were reported in 55 publications, of which 16 provided efficacy and/or safety outcomes on axitinib after therapy with sunitinib or cytokines. In these patients, median progression-free and overall survival ranged between 5.5 and 8.7 months and 11.0 and 69.5 months, respectively. Conclusions: Axitinib is commonly used in clinical practice and has a well-characterised safety and efficacy profile in the treatment of patients with aRCC after the failure of prior therapy with sunitinib or cytokines.

摘要翻译： 

背景：我们开展了一项系统性文献综述，旨在明确晚期肾细胞癌患者在既往细胞因子、酪氨酸激酶抑制剂或免疫检查点抑制剂治疗失败后的临床治疗证据。本文重点总结了阿昔替尼在细胞因子或舒尼替尼治疗失败的晚期肾细胞癌患者中的应用证据。方法：本系统性综述已在PROSPERO平台注册（编号CRD42023492931），严格遵循2020版PRISMA声明及Cochrane指南规范。通过检索MEDLINE、Embase数据库及会议论文集进行系统性文献收集。研究筛选依据人群、干预措施、对照设置、结局指标和研究设计标准进行。结果：在初步筛选的1252篇文献标题/摘要中，共纳入266篇经同行评议的出版物，其中182篇符合纳入标准。另收录28篇会议摘要符合条件。涉及阿昔替尼数据的出版物共55篇，其中16篇提供了舒尼替尼或细胞因子治疗后使用阿昔替尼的疗效和/或安全性结果。该患者群体的中位无进展生存期介于5.5至8.7个月，总生存期介于11.0至69.5个月。结论：阿昔替尼在临床实践中应用广泛，对于舒尼替尼或细胞因子治疗失败的晚期肾细胞癌患者，其安全性与疗效特征已得到充分验证。

原文链接：

Axitinib after Treatment Failure with Sunitinib or Cytokines in Advanced Renal Cell Carcinoma—Systematic Literature Review of Clinical and Real-World Evidence